Patient characteristics modify the association between changes in mineral metabolism parameters and mortality in a nationwide hemodialysis cohort study

被引:0
作者
Goto, Shunsuke [1 ,2 ,3 ]
Hamano, Takayuki [4 ,5 ]
Taniguchi, Masatomo [1 ,6 ]
Abe, Masanori [1 ,7 ]
Nitta, Kosaku [1 ,8 ]
Nishi, Shinichi [2 ,3 ]
Fujii, Hideki [2 ,3 ]
机构
[1] Japanese Soc Dialysis Therapy, Comm Renal Data Registry, Tokyo, Japan
[2] Kobe Univ, Grad Sch Med, Div Nephrol, Kobe, Japan
[3] Kobe Univ Grad Sch Med, Kidney Ctr, Kobe, Japan
[4] Nagoya City Univ, Grad Sch Med Sci, Dept Nephrol, Nagoya, Japan
[5] Osaka Univ, Grad Sch Med, Dept Nephrol, Suita, Japan
[6] Fukuoka Renal Clin, Fukuoka, Japan
[7] Nihon Univ, Sch Med, Dept Internal Med, Div Nephrol Hypertens & Endocrinol, Tokyo, Japan
[8] Tokyo Womens Med Univ, Dept Nephrol, Tokyo, Japan
来源
SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期
关键词
Calcium; Diabetes mellitus; Hemodialysis; Performance status; Phosphate; BONE; CALCIFICATION; PHOSPHATE; CALCIUM;
D O I
10.1038/s41598-025-92359-0
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In hemodialysis patients, it remains unclear whether patient characteristics influence the clinical impacts of changes in serum mineral metabolism parameters on mortality. In this 9-year cohort study, we investigated the associations between the changes in calcium/phosphate levels and all-cause mortality using a time-dependent approach after adjustment for potential confounders in groups stratified by performance status (PS), a history of atherosclerotic cardiovascular disease (ACVD), or diabetic nephropathy (DN). In patients with baseline serum calcium levels of 9.5-<10.0 mg/dL, increases in serum calcium levels were associated with higher mortality exclusively in patients with PS Grade 0. In the same baseline calcium range, a significant association was observed between reduced serum calcium levels and lower mortality only in patients with a history of ACVD or DN. Similarly, in patients with baseline serum phosphate levels of 5.0-<5.5 mg/dL, reduced serum phosphate levels were associated with lower mortality only in those with PS Grade 0, a history of ACVD or DN. These findings indicate that PS should be considered in treating mild hypercalcemia or hyperphosphatemia in hemodialysis patients. Moreover, stringent management of hypercalcemia and hyperphosphatemia in patients with a history of ACVD or DN might be associated with a better prognosis.
引用
收藏
页数:14
相关论文
共 33 条
[1]   A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis [J].
Bhargava, Ramya ;
Kalra, Philip A. ;
Hann, Mark ;
Brenchley, Paul ;
Hurst, Helen ;
Hutchison, Alastair J. .
BMC NEPHROLOGY, 2019, 20 (1)
[2]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[3]   Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder [J].
Fukagawa, Masafumi ;
Yokoyama, Keitaro ;
Koiwa, Fumihiko ;
Taniguchi, Masatomo ;
Shoji, Tetsuo ;
Kazama, Junichiro James ;
Komaba, Hirotaka ;
Ando, Ryoichi ;
Kakuta, Takatoshi ;
Fujii, Hideki ;
Nakayama, Msasaaki ;
Shibagaki, Yugo ;
Fukumoto, Seiji ;
Fujii, Naohiko ;
Hattori, Motoshi ;
Ashida, Akira ;
Iseki, Kunitoshi ;
Shigematsu, Takashi ;
Tsukamoto, Yusuke ;
Tsubakihara, Yoshiharu ;
Tomo, Tadashi ;
Hirakata, Hideki ;
Akizawa, Tadao .
THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 (03) :247-288
[4]   The benefit of reduced serum phosphate levels depends on patient characteristics: a nationwide prospective cohort study [J].
Goto, Shunsuke ;
Hamano, Takayuki ;
Fujii, Hideki ;
Taniguchi, Masatomo ;
Abe, Masanori ;
Nitta, Kosaku ;
Nishi, Shinichi .
CLINICAL KIDNEY JOURNAL, 2024, 17 (10)
[5]   Hypocalcemia and cardiovascular mortality in cinacalcet users [J].
Goto, Shunsuke ;
Hamano, Takayuki ;
Fujii, Hideki ;
Taniguchi, Masatomo ;
Abe, Masanori ;
Nitta, Kosaku ;
Nishi, Shinichi .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (04) :637-647
[6]   Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients [J].
Isaka, Yoshitaka ;
Hamano, Takayuki ;
Fujii, Hideki ;
Tsujimoto, Yoshihiro ;
Koiwa, Fumihiko ;
Sakaguchi, Yusuke ;
Tanaka, Ryoichi ;
Tomiyama, Noriyuki ;
Tatsugami, Fuminari ;
Teramukai, Satoshi .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (03) :723-735
[7]   Association between serum magnesium levels and abdominal aorta calcification in patients with pre-dialysis chronic kidney disease stage 5 [J].
Ito, Mayumi ;
Yamaguchi, Makoto ;
Katsuno, Takayuki ;
Nobata, Hironobu ;
Iwagaitsu, Shiho ;
Sugiyama, Hirokazu ;
Kinashi, Hiroshi ;
Banno, Shogo ;
Ando, Masahiko ;
Kubo, Yoko ;
Ishimoto, Takuji ;
Ito, Yasuhiko .
PLOS ONE, 2021, 16 (06)
[8]   Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism [J].
Kato, Chihiro ;
Fujii, Naohiko ;
Miyakoshi, Chisato ;
Asada, Shinji ;
Onishi, Yoshihiro ;
Fukuma, Shingo ;
Nomura, Takanobu ;
Wada, Michihito ;
Fukagawa, Masafumi ;
Fukuhara, Shunichi ;
Akizawa, Tadao .
BMC NEPHROLOGY, 2020, 21 (01)
[9]   KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Foreword [J].
Wheeler, David C. ;
Winkelmayer, Wolfgang C. .
KIDNEY INTERNATIONAL SUPPLEMENTS, 2017, 7 (01) :12-12
[10]   Lower Parathyroid Hormone Levels are Associated With Reduced Fracture Risk in Japanese Patients on Hemodialysis [J].
Komaba, Hirotaka ;
Imaizumi, Takahiro ;
Hamano, Takayuki ;
Fujii, Naohiko ;
Abe, Masanori ;
Hanafusa, Norio ;
Fukagawa, Masafumi .
KIDNEY INTERNATIONAL REPORTS, 2024, 9 (10) :2956-2969